Because of the frequent overexpression of GRPR in prostate cancer, several bombesin radiopharmaceuticals have been tested in humans for PCa disease detection, including [68Ga]RM2, [68Ga]BAY86-7548, and [64Cu]-CB-TE2A-AR06, among others. Here, GRPR is linked to prostate carcinoma.